NYSE: ASIXAdvansix Inc Stock
$19.95+0.01 (+0.05%)
Updated Apr 17, 2025
ASIX Price
$19.95
Fair Value Price
N/A
Market Cap
$533.54M
52 Week Low
$18.44
52 Week High
$33.00
P/E
12.09x
P/B
0.69x
P/S
0.5x
PEG
0.14x
Dividend Yield
3.21%
Revenue
$1.52B
Earnings
$44.15M
Gross Margin
10.1%
Operating Margin
3.75%
Profit Margin
2.9%
Debt to Equity
1.06
Operating Cash Flow
$135M
Beta
1.32
Next Earnings
May 1, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ASIX Overview
AdvanSix Inc is a chemical company that produces nylon resins and chemicals. It produces phenol through the cumene process for internal use and also sells acetone, phenol, and alpha-methyl styrene. The company sells cyclohexanol and cyclohexanone made from phenol, caprolactam, as well as ammonium sulfate. AdvanSix's nylon resins are used in food, liquid, and consumer packaging. The company was founded in 2016 and is headquartered in Parsippany-Troy Hills, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ASIX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important ASIX news, forecast changes, insider trades & much more!
ASIX News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ASIX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ASIX ($19.95) is trading below its intrinsic value of $57.23, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ASIX is good value based on its earnings relative to its share price (12.09x), compared to the US market average (27.98x)
P/E vs Market Valuation
ASIX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more ASIX due diligence checks available for Premium users.
Valuation
ASIX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
12.09x
Industry
9.73x
Market
27.98x
ASIX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ASIX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ASIX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.69x
Industry
1.02x
ASIX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ASIX price to earnings growth (PEG)
For valuing profitable companies with growth potential
ASIX is good value based... subscribe to Premium to read more.
PEG Value Valuation
ASIX's financial health
Profit margin
Revenue
$329.1M
Net Income
$352.0k
Profit Margin
0.1%
ASIX's Earnings (EBIT) of $56.89M... subscribe to Premium to read more.
Interest Coverage Financials
ASIX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.6B
Liabilities
$820.3M
Debt to equity
1.06
ASIX's short-term assets ($387.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASIX's long-term liabilities ($463.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASIX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ASIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$64.2M
Investing
-$37.5M
Financing
-$24.4M
ASIX's operating cash flow ($135.41M)... subscribe to Premium to read more.
Debt Coverage Financials
ASIX vs Chemical Stocks
Advansix Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.